A Phase 4 interventional study of Atorvastatin 80mg in Arrhythmia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Arrhythmias, Cardiac with a site in Belgium — 10 open to participants now, 14 under way, none of them phase 3. Arrhythmias, Cardiac · Belgium.
Among the 51 studies in Arrhythmias, Cardiac with a site in Belgium, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2000, is the only one in phase 4, and was the 8th registered.
1,051 studies on the registry are indexed under Arrhythmias, Cardiac; 235 are open to participants now.
Browse Arrhythmias, Cardiac studies →10 of the 51 studies in Arrhythmias, Cardiac with a site in Belgium are open now. Recruiting first, the newest first:
Biosense Webster, Inc. · Sites in Belgium, Austria, Germany
Ages 18+
Biotronik, Inc. · Sites in Belgium, United States, Australia and 5 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Belgium, Germany
Ages 18+
Pulse Biosciences, Inc. · Sites in Belgium, Czechia, Italy
Ages 18–75
Qompium NV · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 166 Arrhythmias, Cardiac studies recruiting now, 118 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 1 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 100 across 517 interventional studies indexed under Arrhythmias, Cardiac.
Median enrollment 269 across the 31 interventional studies, 619 across the 20 observational. Of the 34 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 1 study filed under Arrhythmias, Cardiac — fewer than ten, so there is no comparison to draw.
3 of the studies in Arrhythmias, Cardiac with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04735016Medtronic Cardiac Ablation SolutionsDiamondTemp Global Registry | 2026-12-31 |
| NCT07118358Biotronik, Inc.BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System | 2027-03 |
| NCT07727057Biosense Webster, Inc.A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With the TRUPULSE™ Generator for Treatment of Ventricular Arrhythmias | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 51 studies in Arrhythmias, Cardiac with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess in patients with CAD [coronary artery disease] and an implantable defibrillator the effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation requiring ICD [implantable cardioverter defibrillator] intervention) within one year after randomization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR
Exclusion Criteria:
To assess in patients with CAD and an implantable defibrillator the effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular arrhythmia after randomisation.
Combined total mortality and major cardiovascular events.
Major cardiovascular events include acute myocardial infarction, stroke and PTCA [percutaneous coronary angioplasty] (with or without stenting) or CABG [coronary artery bypass graft] (CABG already foreseen at the moment of randomization).
Total number of appropriate ICD interventions for ventricular arrhythmias and total number of episodes of electrical storm.
An episode of electrical storm is defined as the occurrence within 24 hours of three or more ventricular arrhythmias requiring ICD intervention.
Combined total mortality, major cardiovascular events and total number of appropriate ICD interventions for ventricular arrhythmias.
The record gives a start of Feb 2000 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →